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Abstract
Aim This paper aims to unobtrusively identify gender
patterns in diabetics' adherence to their medication regimen.
Subjects and methods Non-adherence is a major problem
in health care as it affects both the patient’s individual
health as well as public health. Seen worldwide, the
problem of non-adherence is even more important due to
the increasing numbers of the elderly population and of
chronic diseases such as diabetes, asthma, HIV, etc. It is
estimated that in Germany alone, non-adherence is
responsible for costs of €10 billion per year. Finding
useful health behaviour patterns could be especially
important for the increasing number of patients with
chronic diseases such as diabetes, where costs are high
and consequences such as retino-, nephro- and neuropathy
severe for 180 million diabetics worldwide. This paper
analyses the records of two German pharmacies, P1 and
P2, regarding gender patterns in adherence to oral
antidiabetics as this analysis method has a high specificity.
Out of 4,474 (P1) respectively 2,650 (P2) datasets, those
were selected that showed the use of medication with
oral drugs for diabetes based on ATC code level A10B.
The selected medication datasets were fully analysed,
also the respective adherence rate for drugs used for
hypertension, ATC code level C.
Results Average adherence rates for oral antidiabetic agents
varied, with 25.4% (P1 women) and 34.6% (P1 men), and
27.8% (P2 women) and 26.1% (P2 men). In contrast,
average adherence rates with drugs for the cardiovascular
system were high, with 73.4% (P1 women) and 74.2% (P1
men), and 57.0% (P2 women) and 70.2% (P2 men).
Conclusion Adherence rates for oral antidiabetic agents
showed no gender patterns. This finding is supported by
varying adherence rates for medication for hypertension. In
both cases, the chi-square test showed no significant
correlation between gender and adherence classification,
and also Cramer’s V only showed a small effect of gender
on adherence behaviour.
Keywords Diabetes . Adherence . Gender .
Pharmacy records
Backgound
It is well known that non-adherence comprises a large part
of the costs in health systems. In Germany alone, non-
adherence is estimated to cause €10 billion in costs per year
(ABDA, Bundesvereinigung Deutsche Apothekerverbände,
7 June 2007). What seems to be missing is a practical and
economical instrument to contain the costs created by this
kind of patient behaviour and to limit disease progression
and co-morbidities.
Finding useful health behaviour patterns could be of
special importance for the increasing number of patients
with chronic diseases, such as diabetes, where costs are
high and consequences like retino-, nephro- and neuropathy
severe for 180 million diabetics worldwide [World Health
Organization (WHO), September 2006]. Because the
difficulty imposed by diabetes is less when patients are
not dealing with severe complications, diabetics seem to be
more susceptible to non-adherence than patients suffering
from other chronic diseases. Furthermore, often existing co-
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morbidities like hypertension demand additional adherent
behaviours.
In Germany, 5–6 million people have been diagnosed
with diabetes; additionally, 1.5 million people with diabetes
are undiagnosed (Lange and Ziese 2007). Ninety percent of
all diabetes patients suffer from type 2, whereas only 5%
have type 1. Based on the data of a 6-year diabetes
intervention study, Benecke researched gender-related
aspects in the rehabilitation of diabetes (Benecke 2005).
Although it is known that gender influences diabetes
prevalence, there are not sufficient detailed research results
about the prevalence and incidence regarding gender
(Benecke 2005). Federal resources revert to figures deter-
mined in 1998 that showed the following distribution: Men
who are 70 years old are more concerned with diabetes than
women of a similar age, but as women age, the situation
changes to the disadvantage of women (Lange and Ziese
2007). An overall higher, gender-independent prevalence of
diabetes in people with poor socioeconomic status is
apparent (Häussler 2006). This is not due to the status,
but to the higher prevalence of diabetes risk factors such as
overweight/obesity and physical inactivity as well as poor
psychological health (Robert Koch Institute, July 2006).
Diabetes in Germany is responsible for €5.16 billion in
direct costs (Lange and Ziese 2007): hospitalisation
accounts for 50%, medication 27%, ambulatory treatment
13% and 10% for other (Icks 2005). Expenses for
complications and co-morbidities have to be added to the
above-mentioned direct costs. In 2002, co-morbidities were
estimated to contribute €9.44 billion to overall diabetes
costs (Häussler 2006). With the increasing number of
diabetics, these costs should be contained. One possible
way is to enhance adherence.
Adherence in terms of health care means the extent to
which patients follow a therapy regimen advised by a
health-care provider (Sabaté 2005; Reymond et al. 2003;
Heuer et al. 1999), including taking medication as well as,
e.g., exercising, dieting and/or changing one’s lifestyle. As
taking drugs seems to be the less complex part when
adhering to an advised therapy, this could be the entry point
for the development of measures to increase overall
adherence rates. When speaking about medication adher-
ence, this includes taking, dosing and timing of the
medication (Heuer et al. 1999).
Regarding the measurement of adherence, diverse
methods are used. The most feasible ways are direct
methods, such as monitoring, measurement of drugs or
metabolites in biological body fluids and measurement of
biological markers as well as indirect methods, such as
“clinical” estimates from medical practitioners or pharma-
cists, therapeutic parameters (e.g., HbA1c), patient diaries,
interviews, drug consumption in relation to prescription,
prescription refill or electronic monitoring (Heuer et al.
1999). Whereas direct methods have a high sensitivity
(Farmer 1999), indirect methods are characterised by high
specificity (Andrade et al. 2006). Each method has
strengths and weaknesses. Direct measures are very
complex and costly, and only applicable in hospitals and
nursing homes or in clinical trials. Indirect measurements
are characterised by high specificity (Andrade et al. 2006)
but retain the basic problem, which is that only the
unpacking of tablets (rather than the taking of the drug)
can be controlled (Vrijens et al. 2005), even with electronic
monitoring.
Reasons for such self-destructive behaviour are multi-
faceted and the subject of health sociology (Gerlinger 2006;
Wolf and Wendt 2006) and health psychology (Renneberg
and Hammelstein 2006; Schwarzer 2004) studies. Salient
are the influences of complex personal conflicts and
problems such as alcohol abuse (Ahmed et al. 2006),
forgetfulness (Vedhara et al. 2004) and patients’ self-
perception (Aalto and Uutela 1997; Horne 1999; Lai and
Cheng 2004). Disease-related factors such as the complexity
of therapy (Claxton et al. 2001; Dezii et al. 2002), cost of
care (Sabaté 2005), psychological strain and acceptance
of the disease pattern in society also play major roles
(Heuer et al. 1999).
Sabaté aggregated existent knowledge and relevant
adherence studies for the World Health Organisation
(WHO) and defined five dimensions of adherence (Sabaté
2005): health-care team/health system factors, therapy-
related, condition-related, social/economic and patient-
related factors. Sabaté identified four clusters that influence
diabetes adherence the most: treatment and disease charac-
teristics, intra-personal and inter-personal factors as well as
environmental factors. Several researchers (Krueger et al.
2005; Fincham 2007; Hearnshaw and Lindenmeyer 2005;
Vermeire et al. 2001), including Cramer (2004), have
provided a summary of the status of adherence research.
But all these summaries simply show that there are no
generalities to be found, with adherence rates ranging from
15–75% (Sabaté 2005) or 36–93% (Cramer 2004). Most
study designs are cross-sectional, which does not serve the
purpose as individual adherence behaviour is situational
and variable over the course of time (Vermeire et al. 2001).
When analysing existing adherence research, it can be
seen that most studies have been conducted in clinical
settings. This limits the informative value significantly as
the conditions are artificial and do not reflect the real
patient situation (Revicki and Frank 1999). Randomised
controlled trials (RCT) are the gold standard when health
technologies are evaluated (Ross et al. 1999) as they should
guarantee a certain study standard and comparability. While
RCTs focus on analysing the efficacy of pharmaceuticals
and health technologies under ideal circumstances with
high internal validity, effectiveness studies try to reflect
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real-world circumstances. Salient are differences regarding
basic characteristics such as the duration of the study as
well as the restriction and homogeneity of patient groups.
Thus, RCTs should run prior to effectiveness studies
(Revicki and Frank 1999).
In clinical studies patients are selected based on the
aim of the study, steadily observed or interviewed with
standardised questionnaires, and do not have to pay for
the study medication. There are no variations from the
previously defined study protocol and generally no
follow-up care. Most interesting is the run-in phase in
which possible participants are rejected who could put
the success of the study at risk, e.g., by being non-
adherent (Farmer 1999). Additionally, there are many
barriers to patients’ participation (Ross et al. 1999;
Robiner et al. 2009), which lead to study results not
representing the comparison group in the population. As a
consequence, findings based on clinical studies cannot
necessarily be adapted to real-world situations.
These discrepancies are well known and are a result of
the described variations in study design, which cause
among other things variations in the impact of the
Hawthorne effect (Hughes and Walley 2003). However,
differences in adherence behaviour have been identified
as the factor with the most influence on outcome
discrepancies (Revicki and Frank 1999; Hughes and
Walley 2003), as the number of non-adherent patients
under real-world circumstances is higher than in clinical
studies (Farmer 1999; Davidson 2006).
The comparability of analyses based on pharmacy
records is questionable as there is no consistent selection
of the relevant data. The present paper follows a different
approach as only those patients with drugs used for diabetes
were selected. Besides, the analysed datasets represent the
real-world behaviour of the selected patients. Further
selection is not useful as this limits the informative power
of the findings. A high level of specificity should be the
aim of an analysis of pharmacy records.
In addition, a validation of a method for adherence
measurement seems problematic only because of the lack of
validated reference values. As no method can provide an
absolute adherence rate—direct methods are influenced by the
Hawthorne effect, clinical studies are artificial, and indirect
methods only measure the unpacking of medication—the
methods should support the aim of a study. This means that
besides a high specificity of pharmacy records, the medication
supply is a reason for this proceeding. As physicians are only
allowed to give a limited number of medication samples,
patients can only be adherent when having enoughmedication
to follow the advised regimen.
The next point of discussion is the use of DDD to
calculate adherence rates. However, as this paper evaluates
gender differences and as DDDs are identified based on
prescription behaviour in Germany, this debate leads to no
useful results and is not of importance here.
Referring to gender patterns, most studies do not even
pay attention to gender or gender-related analyses. Those
noticing gender aspects often report neutrality respectively,
showing a weak influence of gender on adherence
behaviour (Shah et al. 2009; Fitzgerald et al. 1995;
Navuluri 2000; Vermeire et al. 2001). Already in 1981,
Dunn and Turtle came to the conclusion that there is no
diabetic person. Salient are only the differing health beliefs
of women who are more confident with physicians and
medications in general (Navuluri 2000; Vermeire et al.
2001). This could be the reason for the more frequent
consultation of physicians (Benecke 2005), which results in
more prescribed medication, with women receiving on
average 16% more medication than men (Schwabe and
Paffrath 2008). Overall, there seems to be too little research
on gender-related adherence to gain significant insights.
Study design and method
As there is no gold standard for adherence measurement
(Vermeire et al. 2001), the choice of an appropriate method
is essentially based on the aim of the specific study (Farmer
1999). As the majority of studies concerning adherence
research use direct methods for the measurement of
adherence rates, they are not necessarily representative.
Findings have to be analysed in terms of informative power
under real-world circumstances. Studies applying indirect
methods mostly focus on disease-related medication and
thereby only pay attention to single aspects.
The present paper analyses pharmacy records as this
method seems to fit best for researching extensive data with
high specificity (Andrade et al. 2006) and without involv-
ing patients. Obtaining a representative sample of the
population seems possible since German patients generally
use one doctor (Schoen et al. November 2005) and one
pharmacy (ABDA, Bundesvereinigung Deutsche Apothe-
kerverbände, 21 January 2008).
The database for this analysis was extracted from two
different pharmacies in Germany, both belonging to the
same pharmacist. This condition guaranteed consistent data
collection and thereby a consistent database. One pharmacy
(P1) is located in a small countryside town with 6,100
inhabitants and has one competitor; the other one (P2) is
located in a small town with 16,000 inhabitants and has
seven competitors.
Medication data were collected from all individual
pharmacy customers. Medication data not related to
individuals were excluded from this study. P1 has 4,474
datasets of customers who received medication between 1
January 2006 and December 31 2007. Of these, 391 patients
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(8.74%) received diabetes medication. Those patients who
received only insulin (83 patients) as well as patients who died
in 2006 or 2007 were excluded. P2 has 2,650 datasets of
customers who received medication between 1 January 2006
and 31 December 2007. Of these, 240 patients (9.06%)
received diabetes medication. Similarly, patients receiving
only insulin (81 patients) or who died in 2006 or 2007 (8
patients) were excluded.
The percentage of diabetic patients (8.74% and 9.06%,
respectively) is higher than the 7.28% of diagnosed
diabetes patients in the population of Germany. An
explanation could be that the customer distribution in
pharmacies does not necessarily reflect the population’s
distribution of disease patterns as persons with diseases are
overrepresented in this segment.
To extract all relevant patients out of the complete data,
the Anatomical Therapeutic Chemical/Defined Daily Dose
Classification (ATC/DDD Code) was used. The level of
A10 drugs used for diabetes is split into A10A insulin and
analogues, A10B blood glucose-lowering drugs, excluding
insulin and other A10X drugs used in diabetes. Levels
A10A and A10X were excluded due to special dosing
respectively lack of prescription. Based on these ATC
levels, the specific days of coverage for each selected ATC
code were calculated.
In Germany, the official ATC classification is authored
and if necessary adapted by the GKV-Arzneimittelindex im
Wissenschaftlichen Institut der AOK (WIdO) and published
by the Deutsches Institut für Medizinische Dokumentation
und Information (DIMDI). The analysis for this paper was
based on the official code from 2007 to obtain the specific
daily defined dose (DDD) as well as days of coverage. This
method can cause inaccuracies as advised medication regi-
mens do not necessarily match the DDD. But as DDDs are
calculated based on prescription behaviour, the DDD should
represent average consumption (Cosentino et al. 2000).
The collected data included the following: consecutive
number, sex, date of birth, year of birth, health insurance,
number and sum of co-payments for prescriptions and self-
medication, sum of medications and medication dates,
number of prescribed ATC codes, number and coverage of
ATC level A02A antacids, A04 antiemetics and antinauseants,
A11 vitamins, A12 mineral supplements, A13 tonics, G03b
H-androgens, estrogens, progestogens, androgens and female
sex hormones in combination, progestogens and estro-
gens in combination, gonadotropins and other ovulation
stimulants, antiandrogens, N02 analgesics, N05 psycho-
leptics, N06 psychoanaleptics, S01 ophthalmologicals,
S03 ophthalmological and ontological preparations, and
receipt of narcotic substances. For specific analysis of
A10-level and C-level medication (cardiovascular system),
the number, coverage, numbers of different ATC levels and
adherence rates were calculated.
To calculate adherence rates, individual medication data
were sorted according to ATC level and date. The specific
coverages were added to the specific medication dates of
A10- and C-level drugs. The date of the subsequent
prescription conversion was subtracted from the previous
result to calculate the variance in days. The resulting blocks
were condensed into sums per patient for the observation
period.
Adherence rates were calculated as follows: variance in
days/total coverage of drugs with variances. According
to the literature, results were clustered in three groups:
0–19.9% adherent, 20–79.9% partially adherent and 80–
100% non-adherent (Heuer et al. 1999; Reymond et al.
2003; Fincham 2007). For clarity in reporting, result
values exceeding 100% were replaced with 100% and
values below 0% with 0%.
Results
Table 1 shows an overview of the database. P1 and P2
showed a relatively equal distribution of gender with 48.8%
respectively 47.1% female patients receiving A10B medi-
cation (antidiabetics excluding insulin) (Tables 2, 3 and 4).
The average age of 69.5 years in patients in P1 was
4.3 years higher than in P2. The average age of women in
P1 was slightly lower than that of men, whereas the average
age in P2 was quite similar.
Though the database included only datasets of patients
who received A10B medication, not all of those could be
analysed according to adherence rate. If there was not a
subsequent prescription for the respective A10B level, it
was not possible to calculate a variance between coverage
and the next prescription conversion.
Regarding the supply of drugs used in diabetes excluding
insulin, it is striking that patients in the rural P1 received
29% more DDDs than those in the more urban P2. The
average was calculated for the 2-year observation period,
which resulted in 178.6 (P1) respectively 138.4 (P2)
DDDs for 1 year. In total, in 2006 the prescribed number
of DDDs in Germany was 448 for women and 385 for
men (Schwabe and Paffrath 2008). The supply for men in
P1 was 14.4% higher than the supply for women, whereas
in P2 it was almost equal (+ 0.4%).
The low adherence rates in both cases with 30.0% (P1)
respectively 26.9% (P2) are not surprising. But the higher
adherence rate of men in P1 (34.6%) compared to that of
women (25.4%) is noticeable. However, chi-square
showed no significant correlation between gender and
adherence classification, with 3.817 for P1 and 1.130 for
P2. Also Cramer’s V only showed a small effect of gender
on adherence behaviour, with 0.127 for P1 and 0.100
for P2.
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The situation for medication used for the cardiovascular
system is different. As not all diabetics also received C-level
medication, those without information were excluded.
Compared to the supply of antidiabetic agents, the higher
number of average prescribed DDDs for the cardiovascular
system is striking. Whereas there were gender differences
concerning antidiabetic agents at P1, the C-level medication
level for men was 16.8% higher than for women at P2.
However, chi-square test showed no significant correlation
between gender and adherence classification, with 0.042 for
P1 and 1.651 for P2. Also, Cramer’s Vonly showed a small
effect of gender on adherence behaviour, with 0.014 for P1
and 0.143 for P2.
Also the adherence differences were reversed. Whereas
the overall compliance was quite high, with 73.8% (P1)
respectively 64.1% (P2), there was a difference between
adherence of women and men at P2 and almost none at P1.
Discussion
Before discussing the above findings, the validity of an
analysis based on pharmacy records has to be considered.
The literature provides extensive overviews, which come to
varying conclusions (Andrade et al. 2006; Guénette et al.
2005; Fairley et al. 2005; Rickles and Svarstad 2007;
Steiner and Prochazka 1997).
The most important question to focus on is the existence
of gender patterns. First of all, it seems striking that there is
neither a gender pattern regarding diabetes prevalence
(Benecke 2005) nor support from the literature for such a
conclusion regarding adherence. But an overall higher,
gender-independent prevalence of diabetes in people of
poor socioeconomic status exists (Häussler 2006). The
prevalence of non-insulin-dependent diabetes in the lower
classes, with 5.6% respectively 8.5% for men and women,
P1 P2
No. of datasets 4.475 2.650
No. of datasets with A10 antidiabetic medication 391 240
Share of A10 antidiabetics of total datasets 8.74% 9.06%
Calculation base: no. of datasets with A10B
medication
297 157
Women/men/unknown 50.5%/48.8%0.7% 52.2%/47.1%/0.6%
No. of corresponding datasets 145/150/2 74/82/1
Average age in years 69.5 65.2
No. of corresponding datasets 258 120
Average age women/men in years at the end of
observation period
71.2/67.9 65.0/65.4
No. of corresponding datasets 129/129 57/63
Table 1 Overview of the
database
A10B medication (antidiabetics excluding insulin) P1 P2
Average no. of A10B DDD per patient for observation period 357.2 276.8
Women/men 334.5/382.8 277.6/278.8
No. of corresponding datasets 145/150 74/82
Average coverage with A10B medication for observation period 48.9% 37.9%
Women/men 45.8%/52.4% 38.0%/38.2%
No. of datasets with information regarding A10B adherence rate 235 112
Women/men 112/123 50/62
Average adherence rate of patients with A10B medication 30.0% 26.9%
Standard deviation of A10B adherence 34.6% 35.6%
Average A10B adherence women/men 25.4%/34.6% 27.8%/26.1%
No. of corresponding datasets 112/123 50/65
Standard deviation of A10B adherence rate women/men 33.7%/35.0% 37.9%/34.0%
Chi-square* 3.817 1.130
Cramer’s V* 0.127 0.100
Table 2 Analysis of A10B
medication
* with adherence rates clustered
in 3 groups: 0–19.9% non-
adherent, 20.0–79.9% partially
adherent, 80–100% adherent
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is significantly higher than in the middle class (3.5%
respectively 3.4%) and the upper class (2.5% respectively
1.6%) (Häussler 2006).
It has been well researched that poor socioeconomic
status (SES) is linked with higher morbidity and mortality
(Jungbauer-Gans 2006), but the reason behind this effect is
not yet clear. It is apparent that the distribution of risk
factors, e. g., overweight, shows a disproportionate burden
for the poor (Max Rubner Institute 2008), as health
conditions follow the SES (Jungbauer-Gans and Gross
2006). However, this is not due to the status, but to the higher
prevalence of diabetes risk factors, such as overweight/obesity
and physical inactivity as well as worse psychological health
(Robert Koch Institute 2006). This could explain why there is
no gender pattern, though women more often have a low
socioeconomic position (Babitsch 2006). Even in childhood,
this position already is a strong indicator for diabetes for
women, and women are less often able to change this
position (Maty et al. 2008).
Regarding adherence rates resulting from the present
analysis, there is also no identifiable gender-related behaviour.
Neither the number of diabetics in P1 (women 50.5%, men
48.8%) and P2 (women 52.2%, men 47.1%) nor adherence
rates showed a clear pattern.
While in rural P1 the fill-adherence of women with
A10B medication was considerably lower (25.4%) than that
of men (34.6%), the fill-adherence for cardiovascular
medication was almost equal, with 73.4% for women and
74.2% for men. A completely different situation was shown
in the more urban P2, with a fill-adherence for A10B
medication only slightly higher for women than for men
(27.8% women, 26.1% men), whereas the fill-adherence for
cardiovascular medication was clearly higher for men than
for women (57.0% women, 70.2% men).
This led to the first conclusion: that there is no gender
pattern detectable because it does not exist. However, as
medication adherence is influenced by many factors, it
could also be that there is a gender pattern that is overlain
by psychological influences on health. Further research has
to analyse this possibility.
Conclusion
There is a gap in the current diabetic literature on adherence
and gender. Many clinical studies give no insight into
gender patterns and cannot be analysed in retrospect for
gender information, which contributes to the lack of data.
C medication (cardiovascular system) P1 P2
Average no. of C DDDs per patient for observation period 1,622.4 1,288.8
Women/men 1,624.6/1,620.2 1,189.9/1,390.7
No. of corresponding datasets 134/133 60/69
Average coverage with C medication 222.3% 176.6%
Women/men 222.5%/221.8 163.0%/190.5%
No. of datasets with information regarding C adherence rate 243 101
Women/men 122/121 49/51
Average adherence rate of patients with C medication 73.8% 64.1%
Standard deviation of C adherence rate 34.4% 41.4%
Average C adherence women/men 73.4%/74.2% 57.0%/70.2%
No. of corresponding datasets 122 / 121 49/51
Standard deviation of C adherence rate women/men 34.4%/34.5% 41.8%/39.9%
Chi-square* 0.042 1.651
Cramer’s V* 0.014 0143
Table 3 Analysis of C (cardio-
vascular) medication
* with adherence rates clustered
in 3 groups: 0–19.9%
non-adherent, 20.0–79.9%
partially adherent, 80–100%
adherent
Average A10B adherence women/men 25.4%/34.6% 27.8%/26.1%
No. of corresponding datasets 112/123 50/65
Chi-square 3.817 1.130
Cramer’s V with adherence rates clustered in 3 groups: 0–19.9%
non-adherent, 20.0–79.9% partially adherent, 80–100% adherent
0.127 0.100
Average C-adherence women/men 73.4%/74.2% 57.0%/70.2%
No. of corresponding datasets 122/121 49/51
Chi-square* 0.042 1.651
Cramer’s V* 0.014 0.143
Table 4 Comparison of adher-
ence rates
* with adherence rates clustered
in 3 groups: 0–19.9%
non-adherent, 20.0–79.9%
partially adherent, 80–100%
adherent
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The main conclusion that can be drawn based on the
analysed data is the lack of gender patterns when it comes
to adherence. A patient’s decision for or against adherence
seems to be influenced by so many individual factors that it
implies profound multidimensionality. To contain this set of
problems will challenge all actors in health care.
As adherence may vary from situation to situation, other
actors in the health system besides only physicians should
be addressed, because they can give up-to-date information
that represents the real circumstances of the patient’s
situation and can serve as indicators for when to intervene.
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